Thank you.
Many of our international partners have updated the rules to constrain rising drug prices many years ago. The new PMPRB guidelines appear to be quite similar, or drawn directly from those that are already in place in other countries, including those with large pharmaceutical industries, such as the United Kingdom, France, Japan and Australia.
Considering this, would you identify some of the challenges that PMPRB has faced in fulfilling its mandate of protecting Canadians from excessive pharmaceutical prices over the years, and how will these new guidelines help address some of these challenges?